The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans

The deficiently designed and conducted initial clinical development plan and the occurrence of thrombotic thrombocytopenia cases, have marked the first 12-month journey of the AstraZeneca coronavirus disease 2019 (COVID-19) vaccine after it was first administered to humans. When it was authorized, t...

Descripción completa

Detalles Bibliográficos
Autor principal: Dal-Ré, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2023
Materias:
Pharmacovigilance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277994/
https://www.ncbi.nlm.nih.gov/pubmed/35907680
http://dx.doi.org/10.1016/j.therap.2022.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277994/
https://www.ncbi.nlm.nih.gov/pubmed/35907680
http://dx.doi.org/10.1016/j.therap.2022.07.003

Ejemplares similares